Loss of bone with advancing age is accompanied by oxidative stress (OS) and reduced bone formation associated with diminished osteoblast number and increased osteoblast apoptosis. However, the molecular mechanisms underlying these changes are poorly understood;and it is unclear how intermittent administration of parathyroid hormone (PTH) stimulates bone formation in the elderly in the face of these pathologic changes. It is hypothesized that lipid oxidation, the same mechanism implicated in the pathogenesis of atherosclerosis, also adversely affects bone metabolism. Specifically, the lipoxygenase Aloxl 5 causes OS in the skeleton by oxidizing polyunsaturated fatty acids to generate the pro-oxidant 4- hydroxynonenal (4-HNE), leading to activation of p66 [Shc] - a redo signaling protein that further amplifies OS. The combined effects of OS and lipid oxidation reduce the differentiation and survival of osteoblasts via PPARy-mediated actions that decrease Wnt signaling. It is also proposed that PTH attenuates OS by decreasing p66[Shc] activation, suppressing AloxIS expression, and increasing the synthesis of the 4-HNE scavenging enzyme aldehyde dehydrogenase 3a1 (Alclh3a1). To advance these interrelated hypotheses, the contribution of Aloxl5-mediated generation of 4-HNE to the OS and bone loss caused by aging, ovariectomy, or hyperiipidemia in the ApoE knockout (ApoE KO) mouse model of atherosclerosis, will be determined by conditional deletion of Aloxl 5 or conditional overexpression of Aldh3a1. The contribution of OS and PPARy activation to the decline in Wnt signaling, osteoblast number and bone mass in these models will be investigated by deletion of p66[hsc], and by conditional deletion of PPARy from osteoblast progenitors. Finally, the contribution of the anfioxidant property of intermittent PTH to its anabolic efficacy will be studied in aged mice or ApoE KO mice in which OS has been reduced by deletion of p66 [Shc]'We will also investigate the signaling pathways and anti-oxidant enzymes underlying the ability of PTH to attenuate OS. Efforts to determine the contribution of lipid oxidation to the loss of bone mass in aged and hyperlipidemic atherosclerotic mice could establish common mechanisms for osteoporosis and atherosclerosis, and eventually lead to new therapies that simultaneously combat osteoporosis and other age-related diseases. Elucidation of the relevance of PTH-mediated suppression of OS and lipid oxidation to its anabolic efficacy may reveal new approaches for the treatment of osteoporosis.

Public Health Relevance

Osteoporosis is the most common metabolic disorder of old age. The resulting fractures incur high social and monetary costs, and lead to increased mortality. The studies proposed in this project will investigate the contribution of lipid oxidation and oxidative stress (the same mechanisms implicated in atherosclerosis) to the development of osteoporosis;and the possibility that a novel anti-oxidant property of parathyroid hormone, the only FDA-approved anabolic therapy for osteoporosis, contributes to its efficacy in the elderly.

National Institute of Health (NIH)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Arkansas for Medical Sciences
Little Rock
United States
Zip Code
Bartell, Shoshana M; Kim, Ha-Neui; Ambrogini, Elena et al. (2014) FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun 5:3773
Xiong, Jinhu; Piemontese, Marilina; Thostenson, Jeff D et al. (2014) Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone 66:146-54
Iyer, Srividhya; Han, Li; Bartell, Shoshana M et al. (2014) Sirtuin1 (Sirt1) promotes cortical bone formation by preventing ?-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem 289:24069-78
Bellido, Teresita (2014) Osteocyte-driven bone remodeling. Calcif Tissue Int 94:25-34
Manolagas, Stavros C (2014) Wnt signaling and osteoporosis. Maturitas 78:233-7
Jilka, Robert L; O'Brien, Charles A; Roberson, Paula K et al. (2014) Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age. J Bone Miner Res 29:103-17
Manolagas, Stavros C; Kronenberg, Henry M (2014) Reproducibility of results in preclinical studies: a perspective from the bone field. J Bone Miner Res 29:2131-40
Plotkin, Lilian I; Bellido, Teresita (2013) Beyond gap junctions: Connexin43 and bone cell signaling. Bone 52:157-66
Onal, Melda; Piemontese, Marilina; Xiong, Jinhu et al. (2013) Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem 288:17432-40
Zhou, Jian; Ye, Shiqiao; Fujiwara, Toshifumi et al. (2013) Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation. J Biol Chem 288:30064-74

Showing the most recent 10 out of 133 publications